We wouldn't blame 10x Genomics, Inc. (NASDAQ:TXG) shareholders if they were a little worried about the fact that Serge Saxonov, the Co-Founder recently netted about US$1.9m selling shares at an average price of US$62.90. However, it's crucial to note that they remain very much invested in the stock and that sale only reduced their holding by 2.9%.
In fact, the recent sale by Serge Saxonov was the biggest sale of 10x Genomics shares made by an insider individual in the last twelve months, according to our records. So what is clear is that an insider saw fit to sell at around the current price of US$58.19. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. In this case, the big sale took place at around the current price, so it's not too bad (but it's still not a positive).
Insiders in 10x Genomics didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Check out our latest analysis for 10x Genomics
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. 10x Genomics insiders own about US$591m worth of shares (which is 7.7% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
Insiders haven't bought 10x Genomics stock in the last three months, but there was some selling. And there weren't any purchases to give us comfort, over the last year. It is good to see high insider ownership, but the insider selling leaves us cautious. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing 10x Genomics. At Simply Wall St, we found 3 warning signs for 10x Genomics that deserve your attention before buying any shares.
Of course 10x Genomics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.